ascopubs.org

A single-arm, exploratory study of disitamab vedotin (DV) combined with camrelizumab and platinum-based chemotherapy as first-line treatment in patients with HER2 expressing ...

LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET+) NSCLC. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global Summit for ...
ascopubs.org

Intermittent PARP inhibitor regimen in ovarian cancer (IPIROC): A proof-of-concept exploratory pragmatic study (IPIROC#02) using generic rucaparib with pharmacodynamic assessment.

Ways to accelerate the local implementation and adoption of the homologous recombination deficiency (HRD) testing in India. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...